Comprehensive Stock Comparison
Compare Corcept Therapeutics Incorporated (CORT) vs BridgeBio Pharma, Inc. (BBIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | BBIO | 126.3% revenue growth vs CORT's 12.8% |
| Quality / Margins | CORT | 13.0% net margin vs BBIO's -145.3% |
| Stability / Safety | BBIO | Beta 1.04 vs CORT's 1.12 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | BBIO | +90.5% vs CORT's -41.1% |
| Efficiency (ROA) | CORT | 11.8% ROA vs BBIO's -77.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Corcept Therapeutics is a pharmaceutical company focused on developing and commercializing drugs for severe metabolic, oncologic, and neuropsychiatric disorders caused by cortisol excess. It generates revenue primarily from sales of its flagship drug Korlym for Cushing's syndrome, with future growth expected from its pipeline of selective cortisol modulators targeting additional indications. The company's competitive advantage lies in its deep expertise in cortisol modulation and intellectual property around novel glucocorticoid receptor antagonists.
BridgeBio Pharma is a biopharmaceutical company focused on discovering and developing precision medicines for genetic diseases. It generates revenue primarily through drug development partnerships and potential future product sales — though currently in pre-revenue stage with multiple programs in clinical trials. The company's key advantage is its efficient hub-and-spoke operating model that allows rapid development of targeted therapies for rare genetic conditions.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CORT leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). BBIO leads in 1 (Risk & Volatility). 2 tied.
Financial Metrics (TTM)
CORT is the larger business by revenue, generating $761M annually — 1.5x BBIO's $502M. CORT is the more profitable business, keeping 13.0% of every revenue dollar as net income compared to BBIO's -145.3%. On growth, BBIO holds the edge at +25.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CORTCorcept Therapeut… | BBIOBridgeBio Pharma,… |
|---|---|---|
| RevenueTrailing 12 months | $761M | $502M |
| EBITDAEarnings before interest/tax | $47M | -$560M |
| Net IncomeAfter-tax profit | $99M | -$729M |
| Free Cash FlowCash after capex | $142M | -$458M |
| Gross MarginGross profit ÷ Revenue | +98.3% | +94.4% |
| Operating MarginEBIT ÷ Revenue | +5.9% | -113.3% |
| Net MarginNet income ÷ Revenue | +13.0% | -145.3% |
| FCF MarginFCF ÷ Revenue | +18.6% | -91.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.1% | +25.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -23.1% | +28.6% |
Valuation Metrics
| Metric | CORTCorcept Therapeut… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Market CapShares × price | $3.8B | $12.9B |
| Enterprise ValueMkt cap + debt − cash | $3.7B | $12.4B |
| Trailing P/EPrice ÷ TTM EPS | 43.54x | -17.54x |
| Forward P/EPrice ÷ next-FY EPS est. | 97.65x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 78.58x | — |
| Price / SalesMarket cap ÷ Revenue | 4.97x | 25.79x |
| Price / BookPrice ÷ Book value/share | 6.61x | — |
| Price / FCFMarket cap ÷ FCF | 26.68x | — |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), CORT scores 5/9 vs BBIO's 3/9, reflecting solid financial health.
| Metric | CORTCorcept Therapeut… | BBIOBridgeBio Pharma,… |
|---|---|---|
| ROE (TTM)Return on equity | +15.3% | — |
| ROA (TTM)Return on assets | +11.8% | -77.9% |
| ROICReturn on invested capital | +6.2% | — |
| ROCEReturn on capital employed | +6.5% | -80.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.01x | — |
| Net DebtTotal debt minus cash | -$114M | -$560M |
| Cash & Equiv.Liquid assets | $120M | $570M |
| Total DebtShort + long-term debt | $6M | $10M |
| Interest CoverageEBIT ÷ Interest expense | — | -6.10x |
Total Returns (with DRIP)
A $10,000 investment in CORT five years ago would be worth $14,022 today (with dividends reinvested), compared to $9,245 for BBIO. Over the past 12 months, BBIO leads with a +90.5% total return vs CORT's -41.1%. The 3-year compound annual growth rate (CAGR) favors BBIO at 79.9% vs CORT's 19.7% — a key indicator of consistent wealth creation.
| Metric | CORTCorcept Therapeut… | BBIOBridgeBio Pharma,… |
|---|---|---|
| YTD ReturnYear-to-date | -6.5% | -15.0% |
| 1-Year ReturnPast 12 months | -41.1% | +90.5% |
| 3-Year ReturnCumulative with dividends | +71.4% | +482.1% |
| 5-Year ReturnCumulative with dividends | +40.2% | -7.6% |
| 10-Year ReturnCumulative with dividends | +834.6% | +141.3% |
| CAGR (3Y)Annualised 3-year return | +19.7% | +79.9% |
Risk & Volatility
BBIO is the less volatile stock with a 1.04 beta — it tends to amplify market swings less than CORT's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BBIO currently trades 78.3% from its 52-week high vs CORT's 30.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CORTCorcept Therapeut… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 1.04x |
| 52-Week HighHighest price in past year | $117.33 | $84.94 |
| 52-Week LowLowest price in past year | $28.66 | $28.33 |
| % of 52W HighCurrent price vs 52-week peak | +30.4% | +78.3% |
| RSI (14)Momentum oscillator 0–100 | 36.5 | 39.0 |
| Avg Volume (50D)Average daily shares traded | 2.3M | 2.5M |
Analyst Outlook
Wall Street rates CORT as "Buy" and BBIO as "Buy". Consensus price targets imply 91.6% upside for CORT (target: $68) vs 48.8% for BBIO (target: $99).
| Metric | CORTCorcept Therapeut… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $68.40 | $98.92 |
| # AnalystsCovering analysts | 24 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +6.5% | +0.4% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 100 | 307.94 | +207.9% |
| BridgeBio Pharma, I… (BBIO) | 100 | 242.91 | +142.9% |
Corcept Therapeutic… (CORT) returned +40% over 5 years vs BridgeBio Pharma, I… (BBIO)'s -8%. A $10,000 investment in CORT 5 years ago would be worth $14,022 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | $81M | $761M | +836.3% |
| BridgeBio Pharma, I… (BBIO) | $0.00 | $502M | — |
Corcept Therapeutics Incorporated's revenue grew from $81M (2016) to $761M (2025) — a 28.2% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 10.0% | 13.1% | +30.8% |
| BridgeBio Pharma, I… (BBIO) | -6.4% | -145.3% | -2162.2% |
Corcept Therapeutics Incorporated's net margin went from 10% (2016) to 13% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 17.4 | 42.4 | +143.7% |
Corcept Therapeutics Incorporated has traded in a 16x–42x P/E range over 9 years; current trailing P/E is ~44x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 0.07 | 0.82 | +1071.4% |
| BridgeBio Pharma, I… (BBIO) | -0.33 | -3.79 | -1048.5% |
Corcept Therapeutics Incorporated's EPS grew from $0.07 (2016) to $0.82 (2025) — a 31% CAGR.
Chart 6Free Cash Flow — 5 Years
Corcept Therapeutics Incorporated generated $142M FCF in 2025 (-15% vs 2021). BridgeBio Pharma, Inc. generated $-447M FCF in 2025 (+18% vs 2021).
CORT vs BBIO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CORT or BBIO a better buy right now?
Corcept Therapeutics Incorporated (CORT) offers the better valuation at 43.5x trailing P/E (97.6x forward), making it the more compelling value choice. Analysts rate Corcept Therapeutics Incorporated (CORT) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CORT or BBIO?
Over the past 5 years, Corcept Therapeutics Incorporated (CORT) delivered a total return of +40.2%, compared to -7.6% for BridgeBio Pharma, Inc. (BBIO). A $10,000 investment in CORT five years ago would be worth approximately $14K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CORT returned +834.6% versus BBIO's +141.3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CORT or BBIO?
By beta (market sensitivity over 5 years), BridgeBio Pharma, Inc. (BBIO) is the lower-risk stock at 1.04β versus Corcept Therapeutics Incorporated's 1.12β — meaning CORT is approximately 8% more volatile than BBIO relative to the S&P 500.
04Which has better profit margins — CORT or BBIO?
Corcept Therapeutics Incorporated (CORT) is the more profitable company, earning 13.1% net margin versus -145.3% for BridgeBio Pharma, Inc. — meaning it keeps 13.1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CORT leads at 5.9% versus -113.3% for BBIO. At the gross margin level — before operating expenses — CORT leads at 98.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is CORT or BBIO more undervalued right now?
Analyst consensus price targets imply the most upside for CORT: 91.6% to $68.40.
06Which pays a better dividend — CORT or BBIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CORT or BBIO better for a retirement portfolio?
For long-horizon retirement investors, Corcept Therapeutics Incorporated (CORT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.12), +834.6% 10Y return). Both have compounded well over 10 years (CORT: +834.6%, BBIO: +141.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CORT and BBIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.